UCB

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

Retrieved on: 
Lunedì, Giugno 3, 2024
Research institute, Hematopoietic stem cell transplantation, UCB, DSM-IV codes, B cell, Bone marrow, Patient, CCBC, STTR, The Texas Heart Institute, Cancer prevention, Medical director, ALL, AML, Immune system, THI, Catalysis, Risk, Hospital, Lung, Blood, Research, CD34, CGT, Radiation, Infection, CRISPR

This grant will allow 7 Hills to advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial.

Key Points: 
  • This grant will allow 7 Hills to advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial.
  • 7 Hills Pharma aims to increase clinical utilization of cord blood resources and improve patient access to life-saving HSCT.
  • Bone marrow is the tissue that generates red blood cells, platelets, and the white blood cells that comprise the immune system.
  • Dr. Peter Vanderslice is a co-founder of 7 Hills Pharma and a pioneer of small molecule integrin activation.

New Automotive Grade Linux Platform Release Adds Cloud-Native Functionality, RISC-V Architecture and Flutter-Based Applications

Retrieved on: 
Giovedì, Maggio 9, 2024
Cloud, Continuity, Ecosystem, UI, Amazon Web Services, SDV, Toyota, SOC, Amazon Elastic Compute Cloud, Software, Business development, Customer experience, Traction, Research, QEMU, Amazon, UCB, SVP, Socs, Continuous integration, AGL, Flutter, Écu, ISA, Automotive Grade Linux, Running, CES, API, HVAC, AWS, SAN, Architecture, SiFive, Video game

SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Automotive Grade Linux (AGL), a collaborative cross-industry effort developing an open source platform for all Software-Defined Vehicles (SDVs), has announced the latest code release of the AGL platform, UCB 17.0 or "Quirky Quillback."

Key Points: 
  • "Established brands and fast-growing startups within the automotive industry are all embracing SDV technologies," said Stefano Marzani, worldwide technology leader, SDV, AWS.
  • The latest release also includes a vehicle-to-cloud demo application that can be used to access KUKSA.val and CAN signals remotely.
  • Quirky Quillback also includes Toyota's automotive embedded version of Flutter , an open source app and UI development toolkit, that was designed specifically for automotive applications.
  • "We are excited that Automotive Grade Linux is now the home for automotive embedded Flutter, which we believe will become the de facto standard for developing in-vehicle applications."

US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments

Retrieved on: 
Giovedì, Maggio 9, 2024
Nephrology, Gastroenterology, Ophthalmology, Rheumatology, Eli Lilly, DMT, Sun Pharma, AAV, Neurology, Growth, B cell, Disease, Novartis, UCB, Novo Nordisk, Incidence, Patient, GBA1, DMTS, Standard of care, Clinical trial, PD, Dermatology, Pharmaceutical industry

Yet, neurologists are hopeful about new ways to deliver levodopa/carbidopa (the current standard of care), new symptomatic treatments, and potential pathways for future disease modifying treatments (DMTs).

Key Points: 
  • Yet, neurologists are hopeful about new ways to deliver levodopa/carbidopa (the current standard of care), new symptomatic treatments, and potential pathways for future disease modifying treatments (DMTs).
  • Beyond these two anticipated products, one-half of neurologists believe in the possibility of an effective DMT within the next five years.
  • To understand how neurologists would evaluate potential future treatments, Spherix conducted an advanced analysis considering neurologists’ preferences for different modalities, efficacy levels, routes of administration (such as IV infusion, oral, etc.
  • Surprisingly, the results show that the route of administration carries nearly as much weight as efficacy when neurologists evaluate likely utility of future therapies.

Sorcero Generative AI Platform Achieves Breakthrough in Patient Accessibility

Retrieved on: 
Mercoledì, Maggio 8, 2024
Cloud, USDM, Health literacy, AI, Google Cloud, Poster, Health, Abstract, Health care, Publishing, Partnership, Research, UCB, Synthetic media, Patient, Physician, Caregiver, Communication, Empathy, PLS, Generative, Complex, Most, Literacy, Medical device

WASHINGTON, May 8, 2024 /PRNewswire-PRWeb/ -- Sorcero, a leading Google Cloud healthcare and life science ecosystem partner, has developed a revolutionary generative AI (gen AI) solution for creating plain language summaries (PLS) of complex scientific content. This innovative approach aims to bridge the gap between scientific research and public understanding, making critical information more accessible to a broader audience.

Key Points: 
  • To help solve this problem, Sorcero leveraged Google Cloud's AI technology, including Vertex AI and Gemini models, to strengthen its Sorcero AI Platform, enabling faster and more efficient analysis of vast amounts of scientific data.
  • By piloting the generative AI solution from the Sorcero AI Platform on Google Cloud to create patient-accessible summaries and by publishing on this novel patient-centric approach to research publication, we aspire to achieve transparency and empower patients throughout their healthcare journey."
  • Sorcero AI PLS abstracts were more readable and rated with higher quality scores by both medical writers, patients, and patient advocates compared to those written by medical writers—including on compassion and empathy.
  • "The results of this research validate our approach and demonstrate the potential for Generative AI to revolutionize scientific communication and patient engagement."

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

Retrieved on: 
Lunedì, Aprile 15, 2024
FDA, Fear, Safety, Research, Animal, Levetiracetam, Epilepsy, Seizure, UCB, Liver, Patient, MES, Toxicity, CBDS, Medication, PTZ, 1A2, Dietary supplement

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters.

Key Points: 
  • LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters.
  • CBDS maintains improved oral formulation capabilities vs cannabidiol, including tablet and water-based solutions.
  • This data was presented at the prestigious ETDD XVII conference in Miami on June 2nd, 2023, and was well received by the expert audience.
  • Following their presentation at ETDD XVII, London Research & Pharmaceuticals accepted a podium presentation invitation from Dr. Meir Bialer at the EILAT XVII held in Madrid, May 2024.

DATAcc by DiMe Launches Core Measures for Sleep

Retrieved on: 
Mercoledì, Aprile 24, 2024
J&J, Defense Innovation Unit, Sage Bionetworks, Parkinson's disease, TC, Eli Lilly and Company, Boston University, Drug development, Veterans' affairs, Health, National Sleep Foundation, Partnership, Jazz Pharmaceuticals, Research, EHealth, Roche, Alzheimer's disease, Environment, Disease, Duke University, UCB, Medical device, Digital health, Government, GSK, MindMed, Mental health, Patient, TNO, Dime, PD, Dementia, Pharmaceutical industry

BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) released a core set of digital measures and resources for sleep. Together, these will increase the availability of high-quality, standardized, and transparent sleep assessments in a natural environment and transform research and care to advance overall population health. The core digital measures set and resources were developed by a cross-disciplinary group of experts designed to maintain broad applicability across research, care, and multiple disease areas.

Key Points: 
  • BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community ( DATAcc ) by the Digital Medicine Society ( DiMe ) released a core set of digital measures and resources for sleep .
  • Better sleep means better health, and disrupted sleep can indicate or cause chronic conditions ranging from primary sleep disorders to mental health conditions to Parkinson's Disease to Women's health to cardiac conditions and more.
  • "The core digital measures of sleep and accompanying resources now make it more accessible than ever before to incorporate sleep data into trials and care plans where sleep was previously inaccessible.
  • In addition to the core measures and over 15 new resources, the project team also added sleep digital measurement products to the Library of Digital Measurement Products.

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Retrieved on: 
Mercoledì, Aprile 10, 2024
Social media, Hope, HS, Hidradenitis suppurativa, Partnership, Disease, Dermatology, UCB, Patient, Inflammation, Diagnosis, Health, Make

"My UCB colleagues and I are incredibly grateful to those who have already shared their HS journeys and stories as part of the Make HStory campaign.

Key Points: 
  • "My UCB colleagues and I are incredibly grateful to those who have already shared their HS journeys and stories as part of the Make HStory campaign.
  • Their own experiences and personal histories are what will provide hope and a path forward for so many others."
  • UCB is proud to contribute to advancing the understanding of HS and is committed to continuing its mission to address unmet needs for those living with this severe disease.
  • To stay up to date on the latest HS resources, visit https://www.makehstory.com/ and follow Make HStory on Instagram at @MakeHStory and on Facebook at www.facebook.com/makehstory .

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Marzo 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

Retrieved on: 
Giovedì, Marzo 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Gene editing, Data science, Drug discovery, Patient, UCB, UC, Artificial intelligence, Chemical biology, Proximity, Cell biology, Cancer, Faculty, Protein, Student, MTI, Doctor of Philosophy, Therapy, Howard Hughes Medical Institute, MTX, University of California, Berkeley, Toxicology, DSM-IV codes, Pharmaceutical industry

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

Key Points: 
  • The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
  • The UC Berkeley Molecular Therapeutics Initiative (MTI) will create a foundational bridge between fundamental research in rare neurological and metabolic diseases and drug discovery to identify and accelerate novel therapeutic modalities into the clinic.
  • “UC Berkeley is an international nucleus for scientific breakthroughs, such as gene editing and immuno-oncology.
  • “In this way, we are not only advancing R&D but also democratizing it by building industry connections for emerging researchers interested in pursuing a biotech career.”
    The UC Berkeley Molecular Therapeutics Initiative (MTI) seeks to accelerate drug discovery efforts by creating therapeutic modalities that overcome challenges in druggability and address unmet medical need.

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Retrieved on: 
Giovedì, Aprile 4, 2024
Week, Psoriasis, Ankylosing spondylitis, Patient, UCB, HS, Psoriatic arthritis, Injection, Safety, FDA, Food, Pharmaceutical industry

In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.

Key Points: 
  • In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.
  • "We are excited to share progress on our FDA applications.
  • "In addition, the sBLA for the 2mL device presentations aims to offer increased convenience for patients.
  • Approval of the 2mL device presentations would mean that patients would have an alternative one-injection regimen option."